Clinical trial
FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
NCT00349713 · U.S. Army Medical Research and Development Command, U.S. Fed · Completed
Key facts
| NCT number | NCT00349713 |
|---|---|
| Title | FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali |
| Official title | Double Blind Randomized, Controlled Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of the WRAIR AMA1 Malaria Antigen (FMP2.1) Adjuvanted in GSK's AS02A Versus Rabies Vaccine in Malaria-experienced Adults in Bandiagara, Mali |
| Lead sponsor | U.S. Army Medical Research and Development Command, U.S. Fed |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH Walter Reed Army Institute of Research (WRAIR) U.S. Fed GlaxoSmithKline Industry University of Maryland |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malaria, Plasmodium Falciparum Malaria |
| Intervention type | Biological |
| Interventions | FMP2.1/AS02A, Rabies vaccine (RabAvert) |
| Enrollment | 60 |
| Start date | Nov 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Jul 10, 2006 |
| Last update posted | Jul 24, 2017 |
| Countries | Mali |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: